The sphingosine‐1‐phosphate receptor modulator, FTY720, prevents the incidence of diabetes in Spontaneously Diabetic Torii rats. (12th October 2020)

• Record Type: Journal Article
• Authors: Kobayashi, Kazuma; Sasase, Tomohiko; Ishii, Yukihito; Katsuda, Yoshiaki; Miyajima, Katsuhiro; Yamada, Takahisa; Ohta, Takeshi
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 48:Number 6(2021)
• Page Start: 869
• Page End: 876
• Publication Date: 2020-10-12
• Subjects: diabetes -- immunomodulation -- SDT rat -- sphingosine‐1‐phosphate receptor modulator; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.13405
• Languages: English
• ISSNs: 0305-1870

Abstract

Abstract: The sphingosine‐1‐phosphate (S1P) receptor modulator regulates lymphocyte trafficking, resulting in its depletion from circulation, which ultimately causes immunosuppression. In this study, we investigated the preventive effect of fingolimod (FTY720) in the non‐obese type 2 diabetic model, Spontaneously Diabetic Torii (SDT) rats. The S1P receptor modulator, FTY720 (0.3 mg/kg p.o.), was administered for 12 weeks to SDT rats from 5 to 17 weeks of age. Based on our findings, FTY720 could suppress the incidence of diabetes in SDT rats. Further, glucose intolerance was improved in FTY720‐treated SDT rats at 14 weeks of age. Based on the haematological and histological analyses performed at 17 to 18 weeks of age, a decrease in lymphocytes and monocytes in the peripheral blood and a decrease in lymphocyte and atrophy in spleen occurred in the FTY720‐treated SDT rats. Furthermore, the pancreatic changes, such as inflammation, atrophy, and fibrosis in islets observed in SDT rats were improved by FTY720 treatment. These findings suggest that the immunomodulatory effects of FTY720 reduced the pancreatic lesion in SDT rats, thereby demonstrating its preventive effect against diabetes. The development of diabetes in SDT rats is related to disorders of the immune system. However, the S1P receptor modulator may be useful for treating type 2 diabetes. Abstract : A sphingosine‐1‐phosphate (S1P) receptor modulator, FTY720, prevents the development of diabetes in the non‐obese type 2 diabetic model, Spontaneously Diabetic Torii (SDT) rats. Immunomodulatory effects of FTY720 reduce the pancreatic lesion by depleting the circulating lymphocytes. S1P receptor modulator may be useful for treating type 2 diabetes.